Abstract
Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have